ArticleCell transplantation
From "stem" to "stromal": Reframing the nomenclature of mesenchymal stromal cell therapy.
Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesenchymal Stromal Cells in Knee Osteoarthritis: A Review of Nomenclature, Criteria, and Therapeutic Mechanisms.Therapeutics and clinical risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent regulatory approvals and maturing clinical evidence indicate that mesenchymal stromal cells (MSCs) exert therapeutic effects predominantly through paracrine and immunomodulatory mechanisms rather than lineage-driven regeneration. In line with contemporary positions from International Society for Cell & Gene Therapy and Japanese Society for Regenerative Medicine, we argue for mechanism-aligned terminology and propose framing these interventions as MSC-based immunomodulatory therapies. This terminology improves scientific clarity, aligns clinical endpoints and potency assays with the mechanism of action, facilitates coherent regulatory communication, and mitigates public misunderstanding tied to the legacy "stem cell" label.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.